Pharmaceutical Executive Digest Europe - January 14, 2009 - (Page 10) Q&A most expensive. Singapore is not about cost cutting to success, it’s about finding new products and forging partnerships within the resident community. What pharma successes have you had over the last couple of years? Today, 11 of the world’s top pharma and biotech companies, as well as 17 of the top global medical technology companies, have set up more than 45 commercial manufacturing facilities in Singapore. Eli Lilly is one success story. They came to Singapore in 2002 and in 2007 they tripled the size of their investment. They recognised that Asia is the next big growth area and they reasoned that the more they invest here the better they are positioned for the future. In Singapore they found a good location to establish a ‘control tower’ to coordinate their activities throughout the rest of Asia via the new Fully Integrated Pharmaceutical Network (FIPNet) model. The environment here also allows them to experiment, to do things differently than they might in their home country. Singapore allows for pioneering methods of research. rest of the pack. While many countries will see their ability to invest in R&D hampered, we in Singapore are seeing the opposite. Funding for research will Singapore is not about cost cutting to success, it’s about finding new products and forging partnerships within the resident community. Companies today really need to be thinking about new partnerships and, specifically, public-private partnerships. In Singapore we are investing in intellectual capital, in research and development by government institutes and in the infrastructure. We are putting major government spending in place to enable us to restructure our partnership models. Also, we offer tax incentives, as well as developmental research grants, so that we can help companies work out new kinds of public-private partnerships that will work for them. In Singapore you’ll find the right balance of intellectual power and financial incentives to develop products both for the Asian and global markets. The government of Singapore is in a fortunate position in that it has the funds to continue making long-term investments. continue here, as it sends the right message to everyone, Singaporean or otherwise, that we view R&D as a fundamental investment for the future. The government of Singapore is in a fortunate position in that it has the funds to continue making long-term investments. It is the stability of longterm money that attracts people — they don’t have to worry about funding going up and down. They can be confident that they can stay here for 15 years or more. This is what differentiates Singapore from many other places. For more information about investment opportunities, visit www.edb.gov.sg/ edb/sg/en_uk/index/industry_sectors/ pharmaceuticals html Pharma and biotech moves to Singapore World-class pharmaceutical companies with significant operations in Singapore include Abbott, AstraZeneca, Bayer Schering Pharma, Bilcare, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Eisai, GlaxoSmithKline, Lundbeck, Kaneka, Merck & Co., Merck Sereno, Novartis, Novo Nordisk, Pfizer, Sanofi-aventis, Schering-Plough, Takeda and Wyeth. Biotech companies who’ve made the move include A-Bio Pharma, Albany Molecular Research, Austrianova, B2 Labs, CellResearch Corp, Codexis, Combinatorx, CordLife, ES Cell International, Genentech, Genzyme, Greenhills Biotech, KooPrime, Proligo, Lonza, Lynk Biotechnologies, MerLion Pharmaceuticals, Miltenyi Biotec, Newbiomed PIKA, PharmaLogicals Research, ProTherapeutics, pSiOncology, S*BIO, SingVax, Stem Cell Technologies, and Waseda-Olympus Bioscience Research Institute. How is the credit crisis likely to affect Singapore? I believe that the crisis is also an opportunity for strong countries and strong companies to pull away from the 11 STRATEGY FUNDAMENTALS Overcoming institutional theory jargon 13 CALENDAR The next few weeks’ pharma events 2 NEWS Major award for European healthcare agency 4 BRUSSELS REPORT Setbacks for patient communication in Europe http://www.edb.gov.sg/edb/sg/en_uk/index/industry_sectors/pharmaceuticals__.html http://www.edb.gov.sg/edb/sg/en_uk/index/industry_sectors/pharmaceuticals__.html http://www.edb.gov.sg/edb/sg/en_uk/index/industry_sectors/pharmaceuticals__.html
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Digest Europe - January 14, 2009 Pharmaceutical Executive Digest Europe - January 14, 2009 Contents News Brussels Report From the Editor Executive Profile Q&A Strategy Fundamentals Calendar Pharmaceutical Executive Digest Europe - January 14, 2009 Pharmaceutical Executive Digest Europe - January 14, 2009 - Contents (Page 1) Pharmaceutical Executive Digest Europe - January 14, 2009 - News (Page 2) Pharmaceutical Executive Digest Europe - January 14, 2009 - News (Page 3) Pharmaceutical Executive Digest Europe - January 14, 2009 - Brussels Report (Page 4) Pharmaceutical Executive Digest Europe - January 14, 2009 - From the Editor (Page 5) Pharmaceutical Executive Digest Europe - January 14, 2009 - Executive Profile (Page 6) Pharmaceutical Executive Digest Europe - January 14, 2009 - Executive Profile (Page 7) Pharmaceutical Executive Digest Europe - January 14, 2009 - Executive Profile (Page 8) Pharmaceutical Executive Digest Europe - January 14, 2009 - Q&A (Page 9) Pharmaceutical Executive Digest Europe - January 14, 2009 - Q&A (Page 10) Pharmaceutical Executive Digest Europe - January 14, 2009 - Strategy Fundamentals (Page 11) Pharmaceutical Executive Digest Europe - January 14, 2009 - Strategy Fundamentals (Page 12) Pharmaceutical Executive Digest Europe - January 14, 2009 - Calendar (Page 13)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.